^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    1d
    AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) (clinicaltrials.gov)
    P1/2, N=182, Recruiting, AstraZeneca | N=80 --> 182
    Enrollment change
    |
    AZD0120
    3d
    Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy. (PubMed, Bone Marrow Transplant)
    We conducted a single-center retrospective study of 69 patients treated with Tisagenlecleucel, to evaluate the prognostic impact of TP53 alterations (TP53Alt), including mutations and/or deletions...These findings identify TP53 alterations as a strong adverse prognostic factor in patients with r/r B-ALL treated with CAR-T therapy. Screening for TP53Alt may guide risk-adapted strategies, including early consolidation with hematopoietic stem cell transplantation or alternative therapies.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Kymriah (tisagenlecleucel-T)
    4d
    Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. (PubMed, Clin Lymphoma Myeloma Leuk)
    Noncovalent BTK inhibitors, particularly pirtobrutinib, has shown impressive activity in patients who have progressed on covalent BTKi. The FDA approval of lisocabtagene maraleucel represents a significant milestone in the treatment of double refractory CLL, providing a potentially curative option for eligible patients. The development of effective treatments for double refractory CLL represents an urgent unmet clinical need and the promising results from emerging therapies offer hope for improved outcomes in this challenging patient population.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Breyanzi (lisocabtagene maraleucel) • Jaypirca (pirtobrutinib)
    4d
    CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
    P1/2, N=217, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2028 --> Jun 2027
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    5d
    RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, Affiliated Hospital of Nantong University
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    6d
    Circulating CAR T-Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B-Cell Lymphomas and Its Association to Treatment Outcome. (PubMed, Eur J Haematol)
    Our study indicates that CAR T-cell levels after axi-cel correlate to durable response, progression-free survival, and that expansion of CD8+ CAR T-cells might be of specific importance for efficacy. Potentially, CAR T-cell levels may be used to enable early detection of patients with high risk of CAR T-cell treatment failure.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Yescarta (axicabtagene ciloleucel)
    6d
    M-2024-424: MB-CART2019.1 in refractory MS (2024-517601-82-00)
    P1/2, N=25, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    6d
    CARMEN-803: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=0, Withdrawn, University of Utah | N=13 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    7d
    A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=64, Recruiting, Capstan Therapeutics | N=38 --> 64 | Trial completion date: Feb 2026 --> Nov 2027 | Trial primary completion date: Feb 2026 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    7d
    Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CD19 CAR T cells
    7d
    A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Sheba Medical Center
    New P1/2 trial
    |
    TP53 (Tumor protein P53) • CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)